ROCKWELL MEDICAL,INC. (NASDAQ:RMTI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective November28, 2018, Angus Smith commenced employment with Rockwell Medical,Inc. (the “Company”) as the Company’s Chief Financial Officer. Effective upon Mr.Smith’s commencement, the Company’s Board of Directors (the “Board”) appointed Mr.Smith to serve as the Company’s principal financial officer. Mr.Smith succeeds Stuart Paul as principal financial officer.
The additional biographical and other information concerning Mr.Smith as required by Item 5.02(c)of Form8-K was included in the Company’s Current Report on Form8-K filed on November2, 2018 and is incorporated by reference herein.
About ROCKWELL MEDICAL,INC. (NASDAQ:RMTI)
Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its lead branded drug, Triferic is indicated for iron maintenance. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Its generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. It manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.
An ad to help with our costs